Altre lingue BioVie Inc.

Azioni

BIVI

US09074F2074

Tempo reale stimato Cboe BZX Altri mercati azionari 18:23:15 09/07/2024			Variaz. 5gg	Var. 1 gen.
0,41 ^USD	+2,50%		+1,06%	-67,55%

26/06	Transcript : BioVie Inc. - Special Call
25/06	BioVie Inc. presenta il disegno del protocollo del prossimo studio di fase 2 SUNRISE-PD su Bezisterim in pazienti con malattia di Parkinson precoce all'ATMRD 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024	26/06
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024	25/06
BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024	25/06
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress	21/06
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress	20/06
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26	12/06
BioVie Inc. - Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an award from U.S. Department of Defense	05/06
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID	04/06
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients	22/05
BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson?s Disease Patients	22/05
BioVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	14/05
BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	29/04
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID	29/04
BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	29/04
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints	25/04
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation	18/04
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation	26/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI	19/03
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)	18/03
Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI	15/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioVie Inc.

Azioni

BIVI

US09074F2074

Altre lingue

Filtri